Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CEO Michael A. Metzger sold 7,534 shares of Syndax Pharmaceuticals stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $9.29, for a total value of $69,990.86. Following the sale, the chief executive officer owned 298,661 shares of the company's stock, valued at approximately $2,774,560.69. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Syndax Pharmaceuticals Price Performance
Shares of NASDAQ SNDX traded down $0.21 during trading on Friday, reaching $9.46. The company had a trading volume of 1,900,856 shares, compared to its average volume of 1,863,707. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $25.07. The stock has a market capitalization of $814.03 million, a PE ratio of -2.45 and a beta of 0.70. The stock has a 50-day moving average price of $9.91 and a two-hundred day moving average price of $12.21. The company has a current ratio of 5.80, a quick ratio of 5.75 and a debt-to-equity ratio of 1.53.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to analyst estimates of $15.88 million. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. The business's quarterly revenue was up 1900.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.85) earnings per share. As a group, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.
Wall Street Analyst Weigh In
SNDX has been the subject of several recent research reports. Guggenheim restated a "buy" rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. UBS Group reduced their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. The Goldman Sachs Group initiated coverage on shares of Syndax Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $18.00 target price for the company. Finally, Scotiabank boosted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.10.
Check Out Our Latest Stock Report on SNDX
Hedge Funds Weigh In On Syndax Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in SNDX. Quarry LP acquired a new position in Syndax Pharmaceuticals in the first quarter valued at $25,000. Virtus ETF Advisers LLC increased its stake in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares during the last quarter. Magnetar Financial LLC acquired a new position in Syndax Pharmaceuticals in the first quarter valued at $132,000. Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals in the fourth quarter valued at $152,000. Finally, Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals during the fourth quarter worth about $153,000.
Syndax Pharmaceuticals Company Profile
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
